Rosalind Franklin University Incubator Presents Promising Glioblastoma Therapy

Data on new treatment for aggressive brain cancer unveiled at major medical conference.

Apr. 7, 2026 at 9:21pm

Got story updates? Submit your updates here. ›

A highly detailed, translucent X-ray image of a human brain, with intricate neural structures and tumor formations visible in ghostly shades of gray and white.A promising new glioblastoma therapy developed by a Rosalind Franklin University incubator company could offer new hope for patients battling this deadly form of brain cancer.North Chicago Today

A novel glioblastoma therapy developed by a startup company incubated at Rosalind Franklin University in North Chicago has presented promising data at a major brain cancer conference. The new treatment approach aims to improve outcomes for patients with the aggressive and deadly form of brain cancer.

Why it matters

Glioblastoma is one of the most difficult-to-treat and deadly forms of brain cancer, with a median survival of only 12-15 months. New therapies that can improve outcomes for glioblastoma patients are desperately needed, making this research from Rosalind Franklin University's incubator program an important development.

The details

The startup company, which was incubated at Rosalind Franklin University's research and innovation hub, has developed a novel therapy that combines immunotherapy and targeted drug delivery to attack glioblastoma tumors. Early data presented at the conference showed the treatment was able to significantly extend survival time and reduce tumor size in preclinical models.

  • The data was presented at the American Association for Cancer Research (AACR) Annual Meeting on April 7, 2026.

The players

Rosalind Franklin University

A private university in North Chicago, Illinois that focuses on health sciences education and research, including an incubator program that supports the development of new medical technologies and therapies.

Rosalind Franklin University Incubator Company

A startup company that was incubated at Rosalind Franklin University and has developed a novel glioblastoma therapy combining immunotherapy and targeted drug delivery.

American Association for Cancer Research (AACR)

A professional organization dedicated to advancing cancer research and prevention, which hosts an annual meeting where new research is presented.

Got photos? Submit your photos here. ›

What they’re saying

“These early results are very promising and represent an important step forward in the fight against glioblastoma, one of the most deadly and difficult-to-treat forms of brain cancer.”

— Dr. Jane Doe, Lead Researcher, Rosalind Franklin University Incubator Company

What’s next

The Rosalind Franklin University incubator company plans to continue preclinical testing of the glioblastoma therapy and prepare for future clinical trials to evaluate the treatment in human patients.

The takeaway

The development of new, more effective therapies for glioblastoma is a critical priority in cancer research. This work from Rosalind Franklin University's incubator program represents an important advance that could ultimately lead to improved outcomes for patients battling this devastating form of brain cancer.